Literature DB >> 8692972

U1 small nuclear RNA chimeric ribozymes with substrate specificity for the Rev pre-mRNA of human immunodeficiency virus.

A Michienzi1, S Prislei, I Bozzoni.   

Abstract

The in vivo effectiveness of ribozymes strongly depends on the correct choice of the vector molecule. High levels of expression, stability, active conformation, and correct cellular localization are the most important features for a ribozyme vector. We have exploited the utilization of the U1 small nuclear RNA (snRNA) as a vector for specifically targeting a ribozyme into the nucleus. The Rev pre-mRNA of human immunodeficiency virus type 1 was chosen as target for testing the activity of the Ul-ribozyme. The catalytic core of the hammerhead motif, plus the recognition sequences, substituted the stem-loop III of the U1 snRNA. The resulting construct displays efficient cleavage activity in vitro. In addition, in the in vivo system of Xenopus laevis oocytes, the Ul-chimeric ribozyme accumulates in large amounts in the nucleus and produces a considerable reduction of Rev pre-mRNA levels. The Rev-specific ribozyme was also inserted in a derivative of the Ul snRNA mutated in the region of pairing with the 5' splice site, such as to match it with the suboptimal splice junction of the Rev precursor. This construct shows more efficient reduction of Rev pre-mRNA in vivo than the wild-type U1 vector.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8692972      PMCID: PMC38963          DOI: 10.1073/pnas.93.14.7219

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  30 in total

1.  Complete nucleotide sequence of the AIDS virus, HTLV-III.

Authors:  L Ratner; W Haseltine; R Patarca; K J Livak; B Starcich; S F Josephs; E R Doran; J A Rafalski; E A Whitehorn; K Baumeister
Journal:  Nature       Date:  1985 Jan 24-30       Impact factor: 49.962

2.  Simple RNA enzymes with new and highly specific endoribonuclease activities.

Authors:  J Haseloff; W L Gerlach
Journal:  Nature       Date:  1988-08-18       Impact factor: 49.962

3.  A small catalytic oligoribonucleotide.

Authors:  O C Uhlenbeck
Journal:  Nature       Date:  1987 Aug 13-19       Impact factor: 49.962

4.  The Tetrahymena ribozyme acts like an RNA restriction endonuclease.

Authors:  A J Zaug; M D Been; T R Cech
Journal:  Nature       Date:  1986 Dec 4-10       Impact factor: 49.962

5.  Antibodies to small nuclear RNAs complexed with proteins are produced by patients with systemic lupus erythematosus.

Authors:  M R Lerner; J A Steitz
Journal:  Proc Natl Acad Sci U S A       Date:  1979-11       Impact factor: 11.205

6.  Intracellular immunization of human T cells with a hairpin ribozyme against human immunodeficiency virus type 1.

Authors:  O Yamada; M Yu; J K Yee; G Kraus; D Looney; F Wong-Staal
Journal:  Gene Ther       Date:  1994-01       Impact factor: 5.250

7.  In vitro assembly of U1 snRNPs.

Authors:  J Hamm; M Kazmaier; I W Mattaj
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

8.  The accumulation of mature RNA for the Xenopus laevis ribosomal protein L1 is controlled at the level of splicing and turnover of the precursor RNA.

Authors:  E Caffarelli; P Fragapane; C Gehring; I Bozzoni
Journal:  EMBO J       Date:  1987-11       Impact factor: 11.598

9.  Purification of a protein required for the splicing of pre-mRNA and its separation from the lariat debranching enzyme.

Authors:  A Krämer; W Keller
Journal:  EMBO J       Date:  1985-12-16       Impact factor: 11.598

10.  Xenopus laevis U1 snRNA genes: characterisation of transcriptionally active genes reveals major and minor repeated gene families.

Authors:  R Zeller; M T Carri; I W Mattaj; E M De Robertis
Journal:  EMBO J       Date:  1984-05       Impact factor: 11.598

View more
  8 in total

1.  Reduction of target gene expression by a modified U1 snRNA.

Authors:  S A Beckley; P Liu; M L Stover; S I Gunderson; A C Lichtler; D W Rowe
Journal:  Mol Cell Biol       Date:  2001-04       Impact factor: 4.272

2.  Analysis of inhibitory action of modified U1 snRNAs on target gene expression: discrimination of two RNA targets differing by a 1 bp mismatch.

Authors:  Peng Liu; Amy Gucwa; Mary Louise Stover; Emily Buck; Alexander Lichtler; David Rowe
Journal:  Nucleic Acids Res       Date:  2002-06-01       Impact factor: 16.971

Review 3.  Antiviral ribozymes. New jobs for ancient molecules.

Authors:  A Menke; G Hobom
Journal:  Mol Biotechnol       Date:  1997-08       Impact factor: 2.695

4.  Ribozyme-mediated high resistance against potato spindle tuber viroid in transgenic potatoes.

Authors:  X Yang; Y Yie; F Zhu; Y Liu; L Kang; X Wang; P Tien
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-13       Impact factor: 11.205

5.  Preparation and identification of anti-transforming growth factor beta1 U1 small nuclear RNA chimeric ribozyme in vitro.

Authors:  Ju-Sheng Lin; Yu-Hu Song; Xin-Juan Kong; Bin Li; Nan-Zhi Liu; Xiao-Li Wu; You-Xin Jin
Journal:  World J Gastroenterol       Date:  2003-03       Impact factor: 5.742

6.  Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells.

Authors:  Fernanda Gabriella De Angelis; Olga Sthandier; Barbara Berarducci; Silvia Toso; Giuliana Galluzzi; Enzo Ricci; Giulio Cossu; Irene Bozzoni
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-20       Impact factor: 11.205

7.  Dystrophin rescue by trans-splicing: a strategy for DMD genotypes not eligible for exon skipping approaches.

Authors:  Stéphanie Lorain; Cécile Peccate; Maëva Le Hir; Graziella Griffith; Susanne Philippi; Guillaume Précigout; Kamel Mamchaoui; Arnaud Jollet; Thomas Voit; Luis Garcia
Journal:  Nucleic Acids Res       Date:  2013-07-16       Impact factor: 16.971

8.  An Exon-Specific U1snRNA Induces a Robust Factor IX Activity in Mice Expressing Multiple Human FIX Splicing Mutants.

Authors:  Dario Balestra; Daniela Scalet; Franco Pagani; Malgorzata Ewa Rogalska; Rosella Mari; Francesco Bernardi; Mirko Pinotti
Journal:  Mol Ther Nucleic Acids       Date:  2016-10-04       Impact factor: 10.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.